Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Raia DrogasilBSP:RADL3 -1.15%95 14-Day RSI is 49.21 as of Jul. 25, 2026. GuruFocus rates BSP:RADL3 with a GF Score™ of 95/100 and a GF Value™ of R$30.05 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 694 Healthcare Providers & Services companies, Raia Drogasil ranks worse than 66.14% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-25), Raia Drogasil's 14-Day RSI is 49.21.
The industry rank for Raia Drogasil's 14-Day RSI or its related term are showing as below:
BSP:RADL3's 14-Day RSI is ranked worse than 66.14% of 694
companies
in the Healthcare Providers & Services industry
Industry Median: 47.15
vs BSP:RADL3: 49.21
Raia Drogasil (BSP:RADL3) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Raia Drogasil 14-Day RSI Related Terms
Raia Drogasil 14-Day RSI Competitor Comparison
For the Pharmaceutical Retailers subindustry, Raia Drogasil's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raia Drogasil 14-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Raia Drogasil's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Raia Drogasil's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raia Drogasil (BSP:RADL3) has a 14-Day RSI of 49.21 as of Jul. 25, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Raia Drogasil and its competitors. According to the industry distribution chart, Raia Drogasil ranks #459 out of 694 companies in the Healthcare Providers & Services industry, placing it in the top 66.1%.
Is Raia Drogasil's 14-Day RSI too high?
Raia Drogasil's current 14-Day RSI is 49.21. The Healthcare Providers & Services industry median 14-Day RSI is 47.15. Raia Drogasil's value of 49.21 is 4.4% above this industry median. Based on the distribution chart, Raia Drogasil ranks #459 out of 694 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Raia Drogasil has a GF Score™ of 95/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raia Drogasil's 14-Day RSI compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Raia Drogasil ranks #459 out of 694 companies for 14-Day RSI. This places Raia Drogasil in the lower half of its industry. The industry median 14-Day RSI is 47.15. Raia Drogasil's value of 49.21 is 4.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Healthcare Providers & Services company?
The median 14-Day RSI among Healthcare Providers & Services companies is 47.15, based on 694 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raia Drogasil's current 14-Day RSI of 49.21 is 4.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Raia Drogasil and its competitors. For the Healthcare Providers & Services industry, the median 14-Day RSI is 47.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raia Drogasil's current 14-Day RSI is 49.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raia Drogasil stock overvalued right now?
Based on GuruFocus' analysis, Raia Drogasil (BSP:RADL3) is currently considered Significantly Undervalued. The stock's GF Value™ is R$30.05, compared to a current price of R$17.98 — trading 40.2% below its estimated fair value. The current 14-Day RSI is 49.21 and 4.4% above the Healthcare Providers & Services industry median of 47.15. Raia Drogasil's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Raia Drogasil (BSP:RADL3), the current 14-Day RSI is 49.21 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raia Drogasil (BSP:RADL3) Overvalued in 2026?
Based on GuruFocus' analysis, Raia Drogasil stock appears to be undervalued.
The current stock price of R$17.98 is trading 40.2% below its estimated GF Value™ of R$30.05.
GuruFocus considers Raia Drogasil to be Significantly Undervalued.
Key valuation signals for BSP:RADL3:
14-Day RSI: 49.21
GF Value™: R$30.05 vs. price of R$17.98 (40.2% below fair value)
Industry Position: 4.4% above the Healthcare Providers & Services median (#459 of 694)
No single metric tells the full story. See the BSP:RADL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raia Drogasil SA operates a chain of pharmacies in Brazil. The company is mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines. Its pharmacies mainly operate under the Drogasil and Raia brands.
95GF Score
Get the complete analysis for BSP:RADL3
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:RADL3 has been successfully added to your 
